
Energesis Pharmaceuticals Inc Profile last edited on: 11/26/2019
CAGE: 5T2D9
UEI: JA9AEU5KN7R1
Business Identifier: Therapeutics for diabetes, obesity, and lipid disorders: targeting brown adipose tissue (BAT) Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
One Kendall Square Building 200 Suite 2203
Cambridge, MA 02139
Cambridge, MA 02139
(617) 437-0881 |
info@energesispharma.com |
www.energesispharma.com |
Location: Single
Congr. District: 07
County: Middlesex
Congr. District: 07
County: Middlesex
Public Profile
Energesis Pharmaceuticals is a biopharmaceutical company organized around treatment of obesity, diabetes, and related metabolic diseases. The firm's novel approach addresses increasing the body's energy expenditure - specifically to target the expenditure rather than the intake side of the weight maintenance equation: targeting brown adipose tissue (BAT). The Companys approach is a novel strategy leveraging recent scientific insights in BAT biology to increase the bodys ability to burn stored fat and lower insulin resistance. Diabetes and its major underlying cause - obesity - have reached epidemic proportions in the U.S. and the rest of the industrialized world. With very few safe and effective non-invasive treatments for obesity available, and new approaches for diabetes needed, the firm's technology is designed to enable development of drugs that increase energy expenditure, a strategy for addressing both obesity and diabetes that is strongly supported by the scientific literature
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
5-9Revenue Range
.5M-1MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
1-4Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2022 | 2 | NIH | $2,283,948 | |
Project Title: Development of Novel Brown Adipocyte Recruiters for the Treatment of Obesity | ||||
2018 | 2 | NIH | $1,775,543 | |
Project Title: Optimization and Pre-Clinical Studies of a Protein Therapeutic for Recruiting Brown Adipocytes | ||||
2017 | 2 | NIH | $1,781,519 | |
Project Title: Establishing in Vivo Proof of Concept of Brown Adipogenesis Using Approved Drugs | ||||
2015 | 2 | DHA | $1,847,262 | |
Project Title: Cell Culture Approaches to Generating Brown Adipose Tissue for Autologous Transplantation | ||||
2014 | 1 | NIH | $276,203 | |
Project Title: Target Identification Of Proteins And Peptides Capable Of Recruitment Of Brown Ad |
Key People / Management
Olivier Boss -- Chief Scientific Officer, Founder
Brian Freeman -- Chief Operating Officer, Founder
Jean-Paul Giacobino -- Founder
Brian Freeman -- Chief Operating Officer, Founder
Jean-Paul Giacobino -- Founder